Escherichia Coli Peritonitis in Patients Undergoing Peritoneal Dialysis: A Serious Problem that may Get Worse

Bunke C.M. , Brier M.E. , Golper T.A. Outcomes of single-organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52: 524–9.

Troidle L. , Gorban-Brennan N. , Kliger A. , Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32: 623–8.

Krishnan M. , Thodis E. , Ikonomopoulos D. , Vidgen E. , Chu M. , Bargman J.M. Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 2002; 22: 573–81.

Fried L.F. , Piraino B. Peritonitis. In: Gokal R. , Khanna R. , Krediet R. , Nolph K.D. , eds. Textbook of Peritoneal Dialysis. Dordrecht: Kluwer Academic; 2000: 545–64.

Fried L.F. , Bernardini J. , Johnston J.R. , Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176–82.

Tranaeus A. , Heimburger O. , Lindholm B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 1989: 9: 179–90.

Pérez Fontán M. , Rodríguez-Carmona A. , García Naveiro R. , Rosales M. , Villaverde P. , Valdés F. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25: 274–84.

Choi P. , Nemati E. , Banerjee A. , Preston E. , Levy J. , Brown E. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43: 103–11.

Donnenberg M.S. Enterobacteriaceae. In: Mandell G.L. , Bennett J.F. , Dolin R. , eds. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier; 2005: 2567–86.

Westphal J.F. , Brogard J.M. Biliary tract infections: a guide to drug treatment. Drugs 1999; 57: 81–91.

Brook I. , Frazier E.H. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000; 49: 827–30.

Piraino B. , Bailie G.R. , Bernardini J. , Boeschoten E. , Gupta A. , Holmes C. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107–31.

Sepandj F. , Ceri H. , Gibb A. , Read R. , Olson M. Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) in evaluating the antibiotic sensitivity of gram-negative bacilli causing peritonitis. Perit Dial Int 2004; 24: 65–7.

Yip T. , Tse K.C. , Lam M.F. , Tang S. , Li F.K. , Choy B.Y. Risk factors and outcomes of extended spectrum β-lactamase (ESBL)-producing Escherichia coli peritonitis in CAPD patients. Perit Dial Int 2006; 26: 191–7.

Yang C.C. , Chuang F.R. , Hsu K.T. , Chen J.B. , Lee C.H. , Lee C.T. Expanded-spectrum beta-lactamase producing Klebsiella pneumoniae-related peritonitis in a patient on peritoneal dialysis. Am J Kidney Dis 2004; 44: 102–6.

Shah P.M. , Stille W. Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third-generation cephalosporins [Letter]. J Antimicrob Chemother 1983; 11: 597–8.

Jarlier V. , Nicolas M.H. , Fournier G. , Philippon A. Extended broad spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern. Rev Infect Dis 1988; 10: 867–78.

Rupp M.E. , Fey P.D. Extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Drugs 2003; 63: 353–65.

Stürenburg E. , Mack D. Extended spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy and infection control. J Infect 2003; 47: 273–95.

Bradford P.A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933–51.

Bou G. , Cartelle M. , Tomás M. , Canle D. , Molina F. , Moure R. Identification and broad dissemination of the CTX-M-14 β-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol 2002; 40: 4030–6.

Turner P.J. Extended spectrum β-lactamases. Clin Infect Dis 2005; 41(Suppl 4): S273–5.

Queenan A.M. , Foleno B. , Gownley C. , Wira E. , Bush K. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum-β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004; 42: 269–75.

National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth informational supplement M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, formerly NCCLS; 2005.

Linscott A.J. , Brown W.J. Evaluation of four commercially available extended-spectrum β-lactamase phenotypic confirmation tests. J Clin Microbiol 2005; 43: 1081–5.

Colodner R. Extended spectrum β-lactamases: a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005; 33: 104–7.

Smith Moland E. , Hanson N.D. , Herrera V.L. , Black J.A. , Lockhart T.J. , Hossain A. Plasmid-mediated, carbapenem hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51: 711–14.

Valdés-Sotomayor J. , Cirugeda A. , Bajo M.A. , del Peso G. , Escudero E. , Sánchez-Tomero J.A. Increased severity of Escherichia coli peritonitis in peritoneal dialysis patients independent of changes in in vitro susceptibility testing. Perit Dial Int 2003; 23: 450–5.

Caravaca F. , Ruiz-Calero R. , Domínguez C. Risk factors for developing peritonitis caused by microorganisms of enteral origin in peritoneal dialysis patients. Perit Dial Int 1998; 18: 41–5.

Valverde A. , Coque T.M. , Sánchez-Moreno M.P. , Rollán A. , Baquero F. , Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769–75.